Skip to main content
MitoCore Biosciences
← Back to Peptide Library

N-Acetyl Epitalon Amidate

Evidence: E

Experimental / Early Research

1 min readLast reviewed August 17, 2026

Key facts

  • Research areaExperimental / Early Research
  • Study records2
  • Last updated2026-08-17

Evidence Snapshot

Evidence: EVery Limited / Anecdotal Evidence
2026-08-17Last updated

What this grade covers

E for therapeutic efficacy; A-/B for identity only if exact analytical identity is independently confirmed. This subject is primarily useful as an identity / evidence-transfer boundary case study, not a therapeutic-evidence page.

Regulatory Context

No approved therapeutic indication should be claimed for the exact modified analogue.

In Plain English

A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.

What is it?

A chemically modified analogue of parent AEDG/Epitalon: N-terminal acetylation plus C-terminal amidation, commercially described as Ac-Ala-Glu-Asp-Gly-NH2.

Why are researchers interested in it?

Terminal modifications are commonly marketed with claims of improved stability or bioavailability, but no direct pharmacokinetic, stability, or efficacy study of the exact modified molecule was located.

What does the evidence look like?

Evidence grade E for efficacy. A repeated direct search located no PubMed-indexed, PMC-indexed, or clinical-trial evidence for the exact modified analogue.

Biggest things to know

Parent Epitalon/AEDG studies do not establish efficacy, pharmacokinetics, stability, safety, or dosing for Ac-AEDG-NH2. This chemical modification creates a distinct molecular entity requiring its own direct evidence.

Research Takeaway

N-Acetyl Epitalon Amidate is a chemically modified analogue of parent AEDG/Epitalon, not automatically the same experimental entity.

See all 5 evidence claims →

Quick Summary

Experimental / Early Research

N-Acetyl Epitalon Amidate (Ac-AEDG-NH2) is a commercially described N-terminally acetylated, C-terminally amidated analogue of AEDG (Epitalon/Epithalon). No direct indexed therapeutic study of the exact modified molecule has been identified; evidence for the parent peptide Epitalon/AEDG does not transfer to this distinct chemical entity.

Mechanism & Research Overview

No direct mechanistic study of the exact N-acetylated, C-terminally amidated analogue was identified. Improved stability/bioavailability claims commonly made for terminal peptide modifications require direct analytical/pharmacokinetic evidence and must not be inferred from the parent compound.

Evidence Claims

Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.

identity

Supported

N-Acetyl Epitalon Amidate is a chemically modified analogue of parent AEDG/Epitalon, not automatically the same experimental entity.

Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)

Evidence Boundary

Supported

Parent Epitalon studies do not establish efficacy, pharmacokinetics, stability, safety, or dosing for Ac-AEDG-NH2. The same rule applies to N-acetylated, amidated, PEGylated, fragmented, or salt/formulation variants generally.

Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)

human_evidence

Supported

No direct PubMed-indexed, PMC-indexed, or clinical-trial evidence for the exact modified analogue was identified. A negative search does not prove no unpublished/non-indexed experiment exists; the correct wording is that no direct indexed study was identified in this research pass.

Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)

Mechanism

Supported

Improved stability/bioavailability claims commonly made for terminal peptide modifications require direct analytical/pharmacokinetic evidence and must not be inferred from the parent compound.

Regulatory Status

Supported

No approved therapeutic indication should be claimed for the exact modified analogue.

Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check

Safety & Evidence Limitations

Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.

  • Safety Consideration

    Commercial pages frequently extrapolate parent AEDG/Epitalon findings to this distinct modified molecule. That transfer is not scientifically valid without direct study of the modified molecule.

  • Safety Consideration

    No direct PubMed-indexed, PMC-indexed, or clinical-trial evidence for the exact modified analogue was identified in two independent research passes.

Research Areas Being Studied

Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.

Findings Reported in Studies

Educational summary only — reported in cited studies, not a claim of proven benefit.

No Human Study Findings Listed Yet

See preclinical, regulatory, and review sources below.

Study Tables by Evidence Type

2 study records

Human Studies & Clinical Data

No Human Studies & Clinical Data Listed Yet

This section will be updated as sources are added.

Animal / Cell / Preclinical Data

No Animal / Cell / Preclinical Data Listed Yet

This section will be updated as sources are added.

Regulatory Documents & Official Trial Registries(1)

MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check

2026
Population / Model
Dose / Duration / Finding

Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass.

Show full finding
View source

Anecdotal Reported Patterns — Not Medical Advice

Anecdotal Reported Patterns — Not Medical Advice

Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.

Lab Markers to Discuss With a Clinician

Educational topics only — not self-monitoring instructions.

liver and kidney function

FAQ

No. It is a chemically modified analogue (N-terminal acetylation plus C-terminal amidation) of parent AEDG/Epitalon. Evidence for Epitalon does not transfer to this distinct molecule.

Disclaimer

Educational information only. This page summarizes an evidence-transfer boundary case and does not provide medical advice, a recommendation, or instructions for human use.

Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.

Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.

Content status: Content pending review. Last updated 2026-08-17.

Follow research updates for N-Acetyl Epitalon Amidate

Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.

Sign in to follow research updates for N-Acetyl Epitalon Amidate

Get updates when new studies or safety notes are added for this peptide.

Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.

Interests (optional)